These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

542 related items for PubMed ID: 24062327

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus.
    Sheu WH, Park SW, Gong Y, Pinnetti S, Bhattacharya S, Patel S, Seck T, Woerle HJ.
    Curr Med Res Opin; 2015 Mar; 31(3):503-12. PubMed ID: 25629790
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
    Owens DR, Swallow R, Dugi KA, Woerle HJ.
    Diabet Med; 2011 Nov; 28(11):1352-61. PubMed ID: 21781152
    [Abstract] [Full Text] [Related]

  • 6. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
    DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC.
    Diabetes Care; 2015 Mar; 38(3):384-93. PubMed ID: 25583754
    [Abstract] [Full Text] [Related]

  • 7. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.
    Forst T, Uhlig-Laske B, Ring A, Graefe-Mody U, Friedrich C, Herbach K, Woerle HJ, Dugi KA.
    Diabet Med; 2010 Dec; 27(12):1409-19. PubMed ID: 21059094
    [Abstract] [Full Text] [Related]

  • 8. The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Singh-Franco D, McLaughlin-Middlekauff J, Elrod S, Harrington C.
    Diabetes Obes Metab; 2012 Aug; 14(8):694-708. PubMed ID: 22340363
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, Woerle HJ.
    Diabetes Obes Metab; 2011 Jan; 13(1):65-74. PubMed ID: 21114605
    [Abstract] [Full Text] [Related]

  • 10. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
    Søfteland E, Meier JJ, Vangen B, Toorawa R, Maldonado-Lutomirsky M, Broedl UC.
    Diabetes Care; 2017 Feb; 40(2):201-209. PubMed ID: 27913576
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes.
    Durán-Garcia S, Lee J, Yki-Järvinen H, Rosenstock J, Hehnke U, Thiemann S, Patel S, Woerle HJ.
    Diabet Med; 2016 Jul; 33(7):926-33. PubMed ID: 26605991
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.
    Ahmann A, Rodbard HW, Rosenstock J, Lahtela JT, de Loredo L, Tornøe K, Boopalan A, Nauck MA, NN2211-3917 Study Group.
    Diabetes Obes Metab; 2015 Nov; 17(11):1056-64. PubMed ID: 26179619
    [Abstract] [Full Text] [Related]

  • 16. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
    Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, Broedl UC, EMPA-REG MDI Trial Investigators.
    Diabetes Care; 2014 Jul; 37(7):1815-23. PubMed ID: 24929430
    [Abstract] [Full Text] [Related]

  • 17. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
    Rosenstock J, Fonseca VA, Gross JL, Ratner RE, Ahrén B, Chow FC, Yang F, Miller D, Johnson SL, Stewart MW, Leiter LA, Harmony 6 Study Group.
    Diabetes Care; 2014 Aug; 37(8):2317-25. PubMed ID: 24898300
    [Abstract] [Full Text] [Related]

  • 18. Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes.
    Inagaki N, Watada H, Murai M, Kagimura T, Gong Y, Patel S, Woerle HJ.
    Diabetes Obes Metab; 2013 Sep; 15(9):833-43. PubMed ID: 23565760
    [Abstract] [Full Text] [Related]

  • 19. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
    Kovacs CS, Seshiah V, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, Stella P, Woerle HJ, Broedl UC, EMPA-REG EXTEND™ PIO investigators.
    Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.